Advertisement
Research ArticleArticle

Absorption, Metabolism and Excretion of [14C]Mirabegron (YM178), a Potent and Selective β3-Adrenoceptor Agonist, after Oral Administration to Healthy Male Volunteers

Shin Takusagawa, Jan Jaap van Lier, Katsuhiro Suzuki, Masanori Nagata, John Meijer, Walter Krauwinkel, Marloes Schaddelee, Mitsuhiro Sekiguchi, Aiji Miyashita, Takafumi Iwatsubo, Marcel van Gelderen and Takashi Usui
Drug Metabolism and Disposition April 2012, 40 (4) 815-824; DOI: https://doi.org/10.1124/dmd.111.043588

Article Information

vol. 40 no. 4 815-824
DOI 
https://doi.org/10.1124/dmd.111.043588
PubMed 
22269146
Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0090-9556
Online ISSN 
1521-009X
History 
  • Received October 28, 2011
  • Accepted January 23, 2012
  • Published online March 15, 2012.

Article Versions

Copyright & Usage 
Copyright © 2012 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Shin Takusagawa,
  2. Jan Jaap van Lier,
  3. Katsuhiro Suzuki,
  4. Masanori Nagata,
  5. John Meijer,
  6. Walter Krauwinkel,
  7. Marloes Schaddelee,
  8. Mitsuhiro Sekiguchi,
  9. Aiji Miyashita,
  10. Takafumi Iwatsubo,
  11. Marcel van Gelderen and
  12. Takashi Usui
  1. Drug Metabolism Research Laboratories, Astellas Pharma Inc., Osaka, Japan (S.T., K.S., M.N., A.M., T.I., T.U.); PRA International B.V., Zuidlaren, The Netherlands (J.J.v.L.); Drug Metabolism Research Laboratories-Bioanalysis-Europe, Astellas Pharma Europe B.V., Leiderdorp, The Netherlands (J.M.); Astellas Pharma Global Development Inc., Astellas Pharma Europe B.V., Leiderdorp, The Netherlands (W.K., M.Sc., M.v.G.); and Analysis & Pharmacokinetics Research Laboratories, Astellas Pharma Inc., Ibaraki, Japan (M.Se.)
  1. Address correspondence to:
    Shin Takusagawa, Drug Metabolism Research Laboratories, Astellas Pharma Inc., 2-1-6, Kashima, Yodogawa-ku, Osaka 532-8514, Japan. E-mail: shin.takusagawa{at}astellas.com
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: August 2017 to March 2023

AbstractFullPdf
Aug 2017102821
Sep 201774516
Oct 2017125114
Nov 201799717
Dec 2017828013
Jan 2018618615
Feb 20181214518
Mar 20182510014
Apr 201897520
May 2018157418
Jun 2018107618
Jul 2018505116
Aug 201883215
Sep 201814120
Oct 201836919
Nov 2018911024
Dec 2018691611
Jan 20196939
Feb 201976413
Mar 20195103
Apr 20195878
May 20193464
Jun 201933211
Jul 201935612
Aug 20193412
Oct 20194611
Nov 20195892
Dec 20194245
Jan 20204835
Feb 20204830
Mar 20204596
May 20204121
Jun 20204311
Jul 20204074
Aug 20206535
Sep 20204500
Oct 202062210
Nov 20207274
Dec 20202020
Jan 20212412
Feb 20215915
Mar 20214078
Apr 20216255
May 20212351
Jun 20215433
Jul 20213535
Aug 20212736
Sep 20213313
Oct 20213992
Nov 202142312
Dec 20215522
Jan 20224933
Feb 20225351
Mar 20226614
Apr 20227541
May 20222744
Jun 20223981
Jul 202235213
Aug 20224545
Sep 20226712
Oct 202278129
Nov 202264105
Dec 20226624
Jan 20238962
Feb 20235467
Mar 20235232

Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleArticle

ABSORPTION, METABOLISM, AND EXCRETION OF MIRABEGRON

Shin Takusagawa, Jan Jaap van Lier, Katsuhiro Suzuki, Masanori Nagata, John Meijer, Walter Krauwinkel, Marloes Schaddelee, Mitsuhiro Sekiguchi, Aiji Miyashita, Takafumi Iwatsubo, Marcel van Gelderen and Takashi Usui
Drug Metabolism and Disposition April 1, 2012, 40 (4) 815-824; DOI: https://doi.org/10.1124/dmd.111.043588
Reddit logo Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement